CT
JAZZ icon

ClearAlpha Technologies’s Jazz Pharmaceuticals JAZZ Stock Holding History

ClearAlpha Technologies’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,857
Closed -$464K – 286
2024
Q1 		$464K Buy
+3,857
New +$472K 0.2% 134

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

ClearAlpha Technologies's JAZZ Position: Q2 2024 in Review

ClearAlpha Technologies sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 3,857 shares — an estimated $464K sold.

ClearAlpha Technologies first reported a position in JAZZ in Q1 2024 and held it in 1 quarter. The position peaked at $464K in Q1 2024. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • ClearAlpha Technologies reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ClearAlpha Technologies sold 3,857 Jazz Pharmaceuticals shares in Q2 2024, an estimated $464K.
  • ClearAlpha Technologies first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • ClearAlpha Technologies's Jazz Pharmaceuticals position peaked at $464K in Q1 2024.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on ClearAlpha Technologies's 13F filing for Q2 2024, filed 13 Aug 2024.